icon

BVTI:  Biovest International announced on Wednesday that it has established a research collaboration agreement with Ordway Research Institute, a leading biologics research, with a specialized focus on biodefense and emerging infections.

Biovest has been developing BiovaxID to treat non-Hodgkin's ly...

Read more

Shares of OncoVista Innovative Therapies closed higher by nearly thirty percent on Friday with volume four times the daily norm.

OVIT is a company with a very early stage pipeline and is developing cancer treatments that are considered to be less toxic and safer than what's already out there.

The two...

Read more

Shares of ACTC have settled in the high teens after having spiked to nearly thirty cents over the past four months when the company historically received approval from the FDA to commence an embryonic stem-cell based trial for it RPE program in treating severe vision loss.

Shortly after receiving the...

Read more

Those following the Radient story got a dose of what to expect when you're dealing with TheStreet.com's biotech blogger Adam Feuerstein yesterday when the self-proclaimed journalist referred to investors of RPC as "Radient Retards."

I think it's safe to say that anyone left considering this guy a "j...

Read more

Full trial enrollment?

Nope.

Positive trial results?

Uh-uh.

Cytosorbents Corporation announced that it has received CE Mark approval for CytoSorb for the treatment of conditions "where excessive cytokine levels exist", according to a press release issued during the pre-market hours Thursday.

In very sig...

Read more

Biovest International has issued two significant updates over the past couple of weeks regarding BiovaxID, the company's immunotherapeutic treatment for non-Hodgkin's lymphoma.

It's been a volatile history for Biovest and parent company Accentia Biopharmaceuticals (click HERE and follow the links for...

Read more